prednisone has been researched along with Plasmablastic Diffuse Large B-cell Lymphoma in 21 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Case reports and small reviews have evaluated the addition of agents directed against plasma cell disorders in combination with traditional lymphoma-directed regimens." | 1.48 | Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. ( Dittus, C; Ellsworth, S; Grover, N; Park, SI; Tan, X, 2018) |
| "We describe a patient with acquired immunodeficiency syndrome who presented with rectal pain and bright red blood per rectum." | 1.46 | Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma. ( Arora, N; Gupta, A; Sadeghi, N, 2017) |
| "Clinically, primary cutaneous plasmablastic lymphoma presents as non-specific cutaneous lesions (purple nodules, erythematous infiltrated plaques)." | 1.43 | Plasmablastic lymphoma: an atypical cutaneous presentation of a rare entity. ( Carvalho, S; Coelho, A; Lima, M; Mesquita, B; Mota, F; Selores, M; Velho, G, 2016) |
| "Here we present a case of plasmablastic lymphoma with primary site being maxillary sinus, a rare location." | 1.43 | Primary Maxillary Sinus Plasmablastic Lymphoma in HIV/AIDS. ( Basavaraj, A; Kadam, DB; Kadam, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 7 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Rapiti, N | 1 |
| Peer, N | 1 |
| Abdelatif, N | 1 |
| Rapiti, P | 1 |
| Moosa, Y | 1 |
| Jessa, R | 1 |
| Chien, N | 1 |
| Villa, D | 1 |
| Freeman, CL | 1 |
| Slack, GW | 1 |
| Savage, KJ | 1 |
| Scott, DW | 1 |
| Sehn, LH | 1 |
| Song, KW | 1 |
| Gerrie, AS | 1 |
| Jayachandran, PK | 1 |
| Rajan, AK | 1 |
| Karunakaran, P | 1 |
| Mehra, N | 1 |
| Selvarajan, G | 1 |
| Kesana, S | 1 |
| Dhanushkodi, M | 1 |
| Radhakrishnan, V | 1 |
| Sagar, TG | 1 |
| de la Cruz-Benito, B | 1 |
| Lázaro-Del Campo, P | 1 |
| Ramírez-López, A | 1 |
| de Soto-Álvarez, T | 1 |
| Sánchez-Vadillo, I | 1 |
| García-Pérez, E | 1 |
| Dos Santos-Ortas, A | 1 |
| Humala-Barbier, K | 1 |
| López-de la Guía, A | 1 |
| Casado-Abad, G | 1 |
| Jiménez-Yuste, V | 1 |
| Canales-Albendea, M | 1 |
| Marvyin, K | 1 |
| Tjønnfjord, EB | 1 |
| Breland, UM | 1 |
| Tjønnfjord, GE | 1 |
| Ke, YL | 1 |
| Hsiao, HH | 1 |
| Cho, SF | 1 |
| Wu, CC | 1 |
| Castillo, JJ | 2 |
| LaMacchia, J | 1 |
| Flynn, CA | 1 |
| Sarosiek, S | 1 |
| Pozdnyakova, O | 1 |
| Treon, SP | 1 |
| Kobayashi, H | 1 |
| Miyagi, N | 1 |
| Arora, N | 1 |
| Gupta, A | 1 |
| Sadeghi, N | 1 |
| Hunter, NB | 1 |
| Vogt, S | 1 |
| Ambinder, RF | 1 |
| Dittus, C | 1 |
| Grover, N | 1 |
| Ellsworth, S | 1 |
| Tan, X | 1 |
| Park, SI | 1 |
| Guerrero-Garcia, T | 1 |
| Baldini, F | 1 |
| Tchernonog, E | 1 |
| Cartron, G | 1 |
| Ninkovic, S | 1 |
| Cwynarski, K | 1 |
| Dierickx, D | 1 |
| Tousseyn, T | 1 |
| Lansigan, F | 1 |
| Linnik, Y | 1 |
| Mogollon, R | 1 |
| Navarro, JT | 1 |
| Olszewski, AJ | 1 |
| Reagan, JL | 1 |
| Fedele, P | 1 |
| Gilbertson, M | 2 |
| Grigoriadis, G | 2 |
| Bibas, M | 1 |
| Tamura, E | 1 |
| Taniguchi, Y | 1 |
| Nishiyama, M | 1 |
| Yatabe, T | 1 |
| Inoue, K | 1 |
| Arakawa, Y | 1 |
| Mori, M | 1 |
| Ikezoe, T | 1 |
| Terada, Y | 1 |
| Fujimoto, S | 1 |
| Feng, J | 1 |
| Xu, L | 1 |
| Dong, HJ | 1 |
| Zhang, N | 1 |
| Bai, QX | 1 |
| Liang, R | 1 |
| Shu, MM | 1 |
| Yang, L | 1 |
| Chen, XQ | 1 |
| Gu, HT | 1 |
| Gao, GX | 1 |
| Yamada, T | 1 |
| Hara, T | 1 |
| Goto, N | 1 |
| Iwata, H | 1 |
| Tsurumi, H | 1 |
| Zhang, S | 1 |
| Long, C | 1 |
| Fedele, PL | 1 |
| Gregory, GP | 1 |
| Shortt, J | 1 |
| Kumar, B | 1 |
| Opat, S | 1 |
| Koizumi, Y | 1 |
| Uehira, T | 1 |
| Ota, Y | 1 |
| Ogawa, Y | 1 |
| Yajima, K | 1 |
| Tanuma, J | 1 |
| Yotsumoto, M | 1 |
| Hagiwara, S | 1 |
| Ikegaya, S | 1 |
| Watanabe, D | 1 |
| Minamiguchi, H | 1 |
| Hodohara, K | 1 |
| Murotani, K | 1 |
| Mikamo, H | 1 |
| Wada, H | 1 |
| Ajisawa, A | 1 |
| Shirasaka, T | 1 |
| Nagai, H | 1 |
| Kodama, Y | 1 |
| Hishima, T | 1 |
| Mochizuki, M | 1 |
| Katano, H | 1 |
| Okada, S | 1 |
| Mota, F | 1 |
| Mesquita, B | 1 |
| Carvalho, S | 1 |
| Coelho, A | 1 |
| Velho, G | 1 |
| Lima, M | 1 |
| Selores, M | 1 |
| Gui, L | 1 |
| He, XH | 1 |
| Liu, P | 1 |
| Yang, JL | 1 |
| Qin, Y | 1 |
| Zhou, SY | 1 |
| Yang, S | 1 |
| Zhang, CG | 1 |
| Shi, YK | 1 |
| Basavaraj, A | 1 |
| Kadam, M | 1 |
| Kadam, DB | 1 |
2 reviews available for prednisone and Plasmablastic Diffuse Large B-cell Lymphoma
| Article | Year |
|---|---|
Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia.
Topics: Antineoplastic Combined Chemotherapy Protocols; British Columbia; Cyclophosphamide; Doxorubicin; Hum | 2022 |
Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing Outcomes.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2017 |
1 trial available for prednisone and Plasmablastic Diffuse Large B-cell Lymphoma
| Article | Year |
|---|---|
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease-Free Sur | 2019 |
18 other studies available for prednisone and Plasmablastic Diffuse Large B-cell Lymphoma
| Article | Year |
|---|---|
HIV-associated plasmablastic lymphoma: A single-centre 12-year experience in Kwa-Zulu Natal, South Africa.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fe | 2022 |
Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2020 |
Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocol | 2020 |
Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment.
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation | 2020 |
A tip of the iceberg: Disseminated plasmablastic lymphoma, diagnosed from a local oral lesion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Biopsy | 2021 |
Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; B | 2021 |
HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide | 2017 |
Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Retroviral Agents; Antineoplastic Agents; Antineopla | 2017 |
Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
Topics: Adult; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphami | 2018 |
[A Case of Malignancy-induced Lactic Acidosis Having Difficulty with Diagnosis].
Topics: Acidosis, Lactic; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemoradiotherapy; C | 2016 |
[Clinicopathological Characteristics and Prognosis Analysis of the Patients with Plasmablastic Lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; HI | 2018 |
Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols | 2019 |
Pediatric Pharyngeal IgD-positive Monoclonal Plasmacytoid and Plasma Cell Neoplasm.
Topics: Adolescent; Amoxicillin; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clarithromycin | 2015 |
Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dose-Response Re | 2016 |
Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.
Topics: Adult; Anti-Retroviral Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; | 2016 |
Plasmablastic lymphoma: an atypical cutaneous presentation of a rare entity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cycloph | 2016 |
[Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2016 |
Primary Maxillary Sinus Plasmablastic Lymphoma in HIV/AIDS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; HIV In | 2016 |